Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany
- Glitazone pretreatment boosted 1-131 uptake. Foster, Melissa // Endocrine Today;Dec2011, Vol. 9 Issue 12, p24
The article reports on a study which found that a short course of treatment with glitazone before radioiodine ablation enhances the uptake of radioactive iodine by cancer cells which could improve the treatment of metastatic differentiated thyroid cancer.
- Reply. Sabri, O. // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 3, p394
Replies to a comment made on an article about the treatment of differentiated nonmedullary thyroid carcinoma. Effect of thyroid uptake of a second application of radioiodine; Results of a reduction in thyroid uptake; Difficulty in quantifying how much of the administered radioiodine is absorbed...
- Evidence supports optional use of RAI for papillary thyroid cancer. Calabro, Anthony; Costa, Samantha; Foster, Melissa // Endocrine Today;Oct2012, Vol. 10 Issue 10, p16
The article reports that Iain J. Nixon, MBCHB, clinical fellow in the head and neck surgery department of Memorial Sloan-Kettering Cancer Center, has argued for the optional use of radioactive iodine for the management of papillary thyroid cancer.
- Post-therapy whole-body scan with abnormal radioactive iodine localized to the head of two women. Lee, Stephanie L. // Endocrine Today;Jan2011, Vol. 9 Issue 1, p19
This article discusses the case of a young woman who received radioactive iodine remnant ablation for multifocal micropapillary thyroid carcinoma.
- Historical Note: TSH Suppression for Thyroid Cancer. Hurley, James R. // Thyroid;Nov2011, Vol. 21 Issue 11, p1175
The article discusses the suppression of thyroid-stimulating hormone (TSH) for thyroid cancer treatment. The author notes the rapid advances in thyroid disease diagnosis and treatment due to radioiodine availability in the 1940s. He presents some findings on TSH suppression as well as the...
- Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Jarzab, Barbara; Handkiewicz-Junak, Daria; Roskosz, J�zef; Puch, Zbigniew; Wygoda, Zbigniew; Kukulska, Aleksandra; Jurecka-Lubieniecka, Beata; Hasse-Lazar, Kornelia; Turska, Maria; Zajusz, Aleksander // European Journal of Nuclear Medicine & Molecular Imaging;2003, Vol. 30 Issue 8, p1077
We sought to evaluate the efficacy, biochemical effects, safety and outcome of recombinant human thyroid-stimulating hormone (rhTSH) as an adjunct to radioiodine treatment of advanced differentiated thyroid carcinoma (DTC). We also sought to determine whether rhTSH is useful as an adjunct to...
- Three-dimensional radiobiological dosimetry (3D-RD) with I PET for I therapy of thyroid cancer. Sgouros, George; Hobbs, Robert F.; Atkins, Francis B.; Nostrand, Douglas Van; Ladenson, Paul W.; Wahl, Richard L. // European Journal of Nuclear Medicine & Molecular Imaging;May2011 Supplement 1, Vol. 38, p41
Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, I, in combination with positron emission tomography (PET)/CT has...
- Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital. Lee, Ho Young; Chung, June-Key; Lee, Jong Jin; Oh, So Won; Kang, Keon Wook; Park, Do Joon; Cho, Bo Youn; Lee, Myung Chul // Current Medical Imaging Reviews;2010, Vol. 6 Issue 1, p2
Radioactive iodine therapy has played an important role in the management of differentiated thyroid cancer (DTC) since specific accumulation of iodide in the thyroid gland was initially reported. The incidence of thyroid cancer is increasing in many countries including Korea. Conventional RIT...
- Okay to stop radioiodine if it produces no significant effect. Kloos, Richard T.; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p6
The article discusses the use of radioactive iodine as treatment for thyroid disease, according to R. Michael Tuttle, a member at Memorial Sloan Kettering Cancer Center. The general theory is to stop treatment when additional administered activities are unlikely to produce benefit. Clinical...